Page last updated: 2024-12-05

amidephrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amidephrine is a synthetic sympathomimetic amine. It is structurally related to epinephrine, but with an amide group replacing the hydroxyl group at the beta-position. Amidephrine has been studied as a potential therapeutic agent for various conditions, including asthma, hypotension, and nasal congestion. Its effects are primarily mediated by the activation of adrenergic receptors, particularly alpha1- and beta2-adrenergic receptors. Amidephrine is a potent vasoconstrictor, and its bronchodilatory effects are believed to be mediated through the activation of beta2-adrenergic receptors. It has been investigated for its potential in the treatment of asthma, as it may help to relax bronchial smooth muscle and improve airflow. Amidephrine is also known to increase heart rate and blood pressure, and it has been studied as a potential treatment for hypotension. Furthermore, amidephrine has been explored for its potential in the treatment of nasal congestion due to its vasoconstrictive properties.'

amidephrine: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15010
CHEMBL ID146408
CHEBI ID134994
SCHEMBL ID122479
MeSH IDM0067395

Synonyms (49)

Synonym
n-[3-(1-hydroxy-2-methylaminoethyl)phenyl]methanesulfonamide
gtpl514
n-(3-(1-hydroxy-2-(methylamino)-ethyl)phenyl)methanesulfonamide
amidefrine
amidephrine
amidefrine mesilate
CHEBI:134994
CHEMBL146408
mj-5190
mj-1996
amidephrine methanesulfonate
n-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide
L000743
unii-7e2p22546v
amidefrine [inn:ban]
37571-84-9
7e2p22546v ,
3354-67-4
amidefrine [who-dd]
methanesulfonamide, n-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-, (+/-)-
methanesulfonamide, n-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-
3'-(1-hydroxy-2-(methylamino)ethyl)methanesulfonanilide
(+/-)-amidephrine
amidephrine, (+/-)-
amidephrine [mi]
SCHEMBL122479
amidefrin
3'-[1-hydroxy-2-(methylamino)ethyl]methanesulfanilamide
n-(3-[1-hydroxy-2-(methylamino)ethyl]phenyl)methanesulfonamide #
3'-[1-hydroxy-2-(methylamino)ethyl] methanesulfonanilide
ZHOWHMXTJFZXRB-UHFFFAOYSA-N
methanesulfonamide, n-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-, (-)-
u56ldn9fft ,
732186-16-2
ni24n176my ,
unii-u56ldn9fft
amidephrine, (+)-
29430-15-7
methanesulfonamide, n-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-, (+)-
unii-ni24n176my
amidephrine, (-)-
Q4746159
n-{3-[1-hydroxy-2-(methylamino)ethyl]phenyl}methanesulfonamide
bdbm50225291
DTXSID40862664
n-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)methanesulfonamide
CS-0129741
HY-136474
AKOS040750418
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID36715Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID3678350% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID197169Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID1136412Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID1345920Rat alpha1D-adrenoceptor (Adrenoceptors)1994Molecular pharmacology, Nov, Volume: 46, Issue:5
Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (75.68)18.7374
1990's7 (18.92)18.2507
2000's1 (2.70)29.6817
2010's1 (2.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.12 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]